---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-102801"
form_type: "8-K"
ticker: null
cik: "0001834645"
company_name: "Peak Bio, Inc."
filed_at: "2024-09-03T23:59:59+00:00"
generated_at: "2026-05-31T06:40:23.650609+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Interim CEO Stephen LaMond resigns; Executive Chairman Hoyoung Huh assumes CEO duties

## Summary
- Stephen LaMond resigned as Interim CEO and COO, effective Aug 31, 2024; will serve as consultant.
- Separation agreement: $524,300 consulting fee paid in 24 monthly installments starting Sept 1, 2024.
- LaMond receives option for 875,000 shares at $0.80 vesting in three tranches through Dec 31, 2025.
- Board appoints Executive Chairman Hoyoung Huh to assume CEO responsibilities effective Aug 31, 2024.
- Consulting fee includes $24,300 for 6 months of health coverage; COBRA for 18 months.

## SEC filing metadata
- accession: 0000950170-24-102801
- form_type: 8-K
- cik: 0001834645
- company_name: Peak Bio, Inc.
- filed_at: 2024-09-03T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1834645/000095017024102801/0000950170-24-102801-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1834645/000095017024102801/pkbo-20240827.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-102801
- JSON: https://secwatch.observer/filing/0000950170-24-102801.json
- Plain text: https://secwatch.observer/filing/0000950170-24-102801.txt

## Key facts
- Executive change
  Stephen LaMond resigned as Interim Chief Executive Officer and Chief Operating Officer at Peak Bio, Inc..
  - Action: resigned
  - Role: Interim Chief Executive Officer and Chief Operating Officer
  source text: Stephen LaMond, PharmD., MBA resigned from his positions as Interim Chief Executive Officer and Chief Operating Officer of Peak Bio, Inc. (the “Company”), effective August 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1834645/000095017024102801/0000950170-24-102801-index.htm
- Executive change
  Hoyoung Huh was appointed as Chief Executive Officer at Peak Bio, Inc..
  - Action: appointed
  - Role: Chief Executive Officer
  source text: the Company’s Board of Directors (the “Board”) determined that Hoyoung Huh, M.D., PhD, Executive Chairman of the Board, in his capacity as such, would assume the responsibilities of the Company’s chief executive officer, effective August 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1834645/000095017024102801/0000950170-24-102801-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.